ClinicalTrials.gg
CompletedNCT00940225Updated Apr 25, 2024Results posted

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

A Phase 2 interventional study of Cabozantinib and Placebo in Solid Tumors and Cancer, sponsored by Exelixis. Completed at 47 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-25.

Sponsored by Exelixis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
730
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 2 study to evaluate the efficacy and safety of cabozantinib (XL184) in subjects with selected advanced tumor types.

Read the detailed description

The goal of this clinical trial was to learn about the efficacy, safety, and tolerability of cabozantinib against a placebo in subjects with Metastatic Breast Cancer (MBC), Gastric and Gastroesophageal Junction Cancer (GEJ), Hepatocellular Carcinoma (HCC), Melanoma, Non-small Cell Lung Cancer (NSCLC), Ovarian (primary peritoneal or fallopian tube carcinoma), Pancreatic Cancer, Castration-Resistant Prostate Cancer (CRPC), or Small cell Lung Cancer (SCLC) with advanced tumors.

The main questions this study aimed to answer were:

  • What is the efficacy of cabozantinib in subjects with advanced solid tumors?
  • What is the safety and efficacy of cabozantinib at two starting dose levels 100 milligrams (mg) once daily (po QD) and 39.4 mg po QD? Please note: that the 39.4 mg, po QD was only used in the Non-Randomized Expansion (NRE) part of the study

There were three stages to the Randomized Discontinuation Trial (RDT):

  1. The Lead in Stage: This stage enrolled eligible patients with advanced solid tumors who received open-label cabozantinib at 100 mg once daily for 12 weeks.
  2. The Randomized Stage: Subjects who demonstrated stable disease (SD) at the end of 12 weeks of the Lead-in Stage were randomized to receive cabozantinib or placebo (a look-alike substance that contains no active drug) in a blinded manner.

    After randomization, when a patient developed progressive disease (PD), study treatments were discontinued and the treatment blind was broken. If the subject was on a placebo, the subject was offered the opportunity to receive cabozantinib. If the subject was already on cabozantinib, the subject entered the Post-Treatment Period where they were followed until death.

  3. Open-Label Extension: Subjects who were deemed with partial response (PR) or complete response (CR) at Week 12 of the Lead-In Stage were not randomized but allowed to participate in the "Open Label Extension". Patients were given the cabozantinib treatment of 100 mg, po QD.

The emerging data supported enrollment in an open-label, Non-Randomized Expansion cohort (NRE). These cohorts targeted patients with prostate and ovarian cancers. For the patients with prostate, they were assigned to either 100 mg, po QD or 39.4 mg, po QD.

02

Conditions studied

  • Solid Tumors
  • Cancer

Keywords

  • Metastatic Breast Cancer (MBC)
  • Melanoma
  • Stomach or Gastroesophageal Junction Carcinoma (GEJ)
  • Hepatocellular Carcinoma (HCC)
  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Cancer (NSCLC)
  • Ovarian Cancer
  • Pancreatic Cancer
  • Prostate Cancer
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 730 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has a cytologically or histologically and radiologically confirmed, advanced, recurrent, or solid tumor of the nine types listed below:

    • Pancreatic Cancer
    • Castration-Resistant Prostate Cancer (CRPC)
    • Hepatocellular Carcinoma (HCC)
    • Gastric or Gastroesophageal Junction Cancer
    • Melanoma
    • Small Cell Lung Cancer (SCLC)
    • Ovarian cancer, primary peritoneal or fallopian tube carcinoma
    • Breast cancer that is one of the following subtypes: estrogen receptor positive breast cancer, estrogen receptor/progesterone receptor/-negative (triple-negative), or inflammatory (regardless of receptor status) disease histology
    • Non-Small Cell Lung Cancer (NSCLC)
  • Certain requirements for prior therapies may apply
  • The subject has documented progressive disease at screening
  • Subjects having any tumor type of other than CRPC must have at least one lesion that is not within a previously irradiated field and is measurable on CT or MRI scan
  • The subject has recovered to baseline or ≤ Grade 1 from toxicities related to prior treatment (some exceptions apply)
  • The subject is ≥ 18 years old on the day of consent
  • Tissue samples from archival or fresh tissue, or a tissue block of the subject's tumor
  • The subject has an (ECOG) performance status of 0 or 1
  • The subject has adequate organ function
  • The subject is capable of understanding and complying with the protocol requirements and has signed the document
  • Sexually active fertile subjects (male and female), and their partners, must agree to use medically accepted methods of during the course of the study and for 3 months after the last dose of the study drug(s)
  • Female subjects of must have a negative pregnancy test at screening

Exclusion criteria

Exclusion Criteria:

  • The subject has experienced clinically-significant hematemesis or hemoptysis of >0.5 teaspoon of red blood, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
  • The subject has a cavitating pulmonary lesion(s) or a pulmonary lesion abutting or encasing a major blood vessel
  • Certain restrictions on prior treatments apply
  • The subject has known symptomatic or uncontrolled or epidural disease
  • The subject has /International Normalized Ratio (PT/INR) or partial thromboplastin time (PTT) test results that are above (1.3x)the laboratory
  • The subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or Coumadin-related agents, heparin, thrombin or FXa inhibitors, and antiplatelet agents (low-dose aspirin (≤81 mg/day), low-dose warfarin (≤1mg/day, and prophylactic low molecular weight heparin (LMWH) are permitted)
  • The subject has a interval(QTcF)>500 ms at screening
  • The subject has uncontrolled, significant intercurrent illness
  • The subject is unable to swallow capsules
  • The subject is pregnant or breastfeeding
  • The subject has a previously-identified allergy or to components of the study treatment formulation
  • The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
  • The subject has had another diagnosis of requiring systemic treatment within the last two years, unless non-melanoma skin cancer, in-situ carcinoma of the cervix, or superficial bladder cancer
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
730 participants (actual)

Study arms

  • Experimental
    Lead-in Stage - cabozantinib (XL184)

    Open Label, cabozantinib, 100 mg, po QD for 12 weeks.

    Drug: Cabozantinib

  • Experimental
    Randomized Stage - cabozantinib (XL184)

    Blinded, cabozantinib, 100 mg, po QD until disease progression.

    Drug: Cabozantinib

  • Placebo comparator
    Randomized Stage - placebo

    Blinded, placebo, 100 mg, po QD until disease progression.

    Drug: Placebo

  • Experimental
    Open-Label Extension - cabozantinib (XL184)

    Open Label, cabozantinib, for subjects that were on placebo during the randomized stage, 100 mg, po QD until disease progression or unacceptable toxicity.

    Drug: Cabozantinib

  • Experimental
    Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 100mg

    Open Label, cabozantinib, 100 mg, po QD until disease progression or unacceptable toxicity.

    Drug: Cabozantinib

  • Experimental
    Non-Randomized Expansion (NRE) Cohort - Castrate Resistant Prostate Cancer (CRPC), 39.4mg

    Open Label, cabozantinib, 39.4, po QD until disease progression or unacceptable toxicity.

    Drug: Cabozantinib

  • Experimental
    A. Non-Randomized Expansion (NRE) Cohort - Ovarian

    Open Label, cabozantinib, 100 mg, po QD until disease progression or unacceptable toxicity.

    Drug: Cabozantinib

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only

    Objective response rate (ORR) per modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.0 per investigator The analysis of ORR in the RDT Cohorts were defined as the proportion of subjects with a best overall response of confirmed complete response (CR) or partial response (PR) per mRECIST 1.0 during the 12-week Lead-In Stage. In the NRE Ovarian Cohort, mRECIST 1.1 was used. ORR for the NRE CRPC Cohorts was not a primary objective and is therefore not captured in the table below.

    Time frame: From initial dose through final study visit up to 44 months

  2. Bone Scan Response (BSR) - NRE, CRPC

    The reduction of bone scan lesion area (BSLA) by \> 30% was used as the quantitative measure of BSR. BSR was a primary outcome measure for only the NRE CRPC Cohorts.

    Time frame: From initial dose through final study visit up to 15 months

  3. Progression-Free Survival (PFS) - Randomized Stage, RDT Cohorts Only

    Progression Free Survival during the Randomized Stage (Randomized Population)

    Time frame: From initial dose through final study visit up to 44 months

Secondary outcomes

  1. Duration of Objective Response (OR) - Responders From Lead-in Stage

    Duration of objective response was defined as the time from the tumor assessment that first documented PR or CR that was subsequently confirmed at least 28 days later until the date of documented progression. There were either few or no responders in the Gastric/GEJ, SCLC, and pancreatic cohorts so these cohorts are excluded.

    Time frame: From initial dose through final study visit up to 44 months

  2. Progression Free Survival (PFS) - Throughout the Study

    Progression-free survival (PFS) from first dose throughout the study was estimated for all subjects (safety population) using a piecewise method.

    Time frame: From initial dose through final study visit up to 44 months

  3. Duration of Bone Scan Response - NRE Cohorts, CRPC Only

    The duration of BSR per IRF was calculated for CRPC subjects with an objective response (CR or PR) during the study.

    Time frame: From initial dose through final study visit up to 15 months

  4. Overall Survival (OS) - NRE Cohorts, CRPC and Ovarian Only

    Time frame: From initial dose through final study visit up to 15 months

07

Results

Posted Apr 25, 2024

Participant flow

Participant flow — Overall Study
MilestoneRDT Cohort - Castration-Resistant Prostate Cancer (CRPC)RDT Cohort - MelanomaRDT Cohort - Non-Small Cell Lung Cancer (NSCLC)RDT Cohort - Pancreatic CancerRDT Cohort - Gastric/Gastroesophageal Junction Cancer (GEJ)RDT Cohort - Hepatocellular Carcinoma (HCC)RDT Cohort - Small Cell Lung Cancer (SCLC)RDT Cohort - Ovarian CancerRDT Cohort - Metastatic Breast Cancer (MBC)NRE Cohort - CRPC 100 mgNRE Cohort - CRPC 39.4 mgNRE Cohort - Ovarian Cancer 100mg
Started1717760202141217045935160
Completed1566647161936206041874854
Not completed1511134251104636

Outcome measures

PrimaryObjective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only

Objective response rate (ORR) per modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.0 per investigator The analysis of ORR in the RDT Cohorts were defined as the proportion of subjects with a best overall response of confirmed complete response (CR) or partial response (PR) per mRECIST 1.0 during the 12-week Lead-In Stage. In the NRE Ovarian Cohort, mRECIST 1.1 was used. ORR for the NRE CRPC Cohorts was not a primary objective and is therefore not captured in the table below.

Time frame:
From initial dose through final study visit up to 44 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only
percentage of participantsLead-in Stage - CRPCLead-in Stage - MelanomaLead-in Stage - NSCLCLead-in Stage - Pancreatic CancerLead-in Stage - Gastric/GEJLead-in Stage - Hepatocellular CarcinomaLead-in Stage - SCLCLead-in Stage - Ovarian CancerLead-in Stage - Metastatic Breast CancerLead-in Stage - NRE Ovarian Cancer
Objective Response Rate (ORR) - LEAD IN STAGE, RDT Cohorts and NRE Ovarian Cohort Only4.7 (2.0 to 8.7)5.2 (1.8 to 12.4)10 (4.4 to 20.3)0 (0 to 15.4)4.8 (0.2 to 21.8)4.9 (0.9 to 16.1)4.8 (0.2 to 21.8)21.7 (13.1 to 32.4)13.6 (6.0 to 25.7)10.0 (3.3 to 21.8)
PrimaryBone Scan Response (BSR) - NRE, CRPC

The reduction of bone scan lesion area (BSLA) by \> 30% was used as the quantitative measure of BSR. BSR was a primary outcome measure for only the NRE CRPC Cohorts.

Time frame:
From initial dose through final study visit up to 15 months
Reported as:
Number · percentage of participants
Bone Scan Response (BSR) - NRE, CRPC
percentage of participantsNRE Cohort - CRPC 100 mgNRE Cohort - CRPC 39.4 mg
Bone Scan Response (BSR) - NRE, CRPC74.2 (64.1 to 82.7)47.1 (32.9 to 61.5)
PrimaryProgression-Free Survival (PFS) - Randomized Stage, RDT Cohorts Only

Progression Free Survival during the Randomized Stage (Randomized Population)

Time frame:
From initial dose through final study visit up to 44 months
Reported as:
Median · months
Progression-Free Survival (PFS) - Randomized Stage, RDT Cohorts Only
monthsRandomized Phase - CRPC, Cabozantinib ArmRandomized Phase - CRPC, Placebo ArmRandomized Phase - Melanoma, Cabozantinib ArmRandomized Phase - Melanoma, Placebo ArmRandomized Phase - NSCLC, Cabozantinib ArmRandomized Phase - NSCLC, Placebo ArmRandomized Phase - Pancreatic Cancer, Cabozantinib ArmRandomized Phase - Pancreatic Cancer, Placebo ArmRandomized Phase - Gastric/GEJ, Cabozantinib ArmRandomized Phase - Gastric/GEJ , Placebo ArmRandomized Phase - HCC, Cabozantinib ArmRandomized Phase - HCC, Placebo ArmRandomized Phase - SCLC, Cabozantinib ArmRandomized Phase - SCLC, Placebo ArmRandomized Phase - Ovarian Cancer, Cabozantinib ArmRandomized Phase - Ovarian Cancer, Placebo ArmRandomized Phase - MBC, Cabozantinib ArmRandomized Phase - MBC, Placebo Arm
Progression-Free Survival (PFS) - Randomized Stage, RDT Cohorts Only5.5 (4.0 to 8.5)1.4 (1.25 to 2.73)4.5 (1.8 to 15.4)2.8 (1.45 to 5.45)2.4 (1.3 to 2.9)2.4 (1.4 to 2.7)2.8 (1.5 to 2.8).07 (.07 to .07)NA (2.3 to NA)1.0 (.72 to 1.38)2.5 (1.3 to 6.8)1.4 (1.3 to 4.2)5.5 (1.9 to 6.9)1.5 (.85 to 2.23)4.9 (3.9 to 13.6)1.4 (1.3 to 1.6)6.9 (5.1 to 13.5)1.1 (.7 to 1.3)
SecondaryDuration of Objective Response (OR) - Responders From Lead-in Stage

Duration of objective response was defined as the time from the tumor assessment that first documented PR or CR that was subsequently confirmed at least 28 days later until the date of documented progression. There were either few or no responders in the Gastric/GEJ, SCLC, and pancreatic cohorts so these cohorts are excluded.

Time frame:
From initial dose through final study visit up to 44 months
Reported as:
Median · Months
Duration of Objective Response (OR) - Responders From Lead-in Stage
MonthsCRPCMelanomaNSCLCHepatocellular CarcinomaOvarian CancerMetastatic Breast Cancer
Duration of Objective Response (OR) - Responders From Lead-in Stage5.59 (4.27 to 8.34)5.55 (2.99 to 13.86)6.90 (5.29 to 10.74)4.21 (2.99 to NA)11.24 (7.20 to NA)3.29 (2.79 to 4.21)
SecondaryProgression Free Survival (PFS) - Throughout the Study

Progression-free survival (PFS) from first dose throughout the study was estimated for all subjects (safety population) using a piecewise method.

Time frame:
From initial dose through final study visit up to 44 months
Reported as:
Median · months
Progression Free Survival (PFS) - Throughout the Study
monthsCRPCMelanomaNSCLPancreatic CancerGastric/GEJHepatocellular CarcinomaSCLCOvarian CancerMetastatic Breast Cancer
Progression Free Survival (PFS) - Throughout the Study6.8 (3.9 to 9.7)2.8 (1.4 to 6.9)4.0 (1.4 to 5.7)2.7 (1.3 to 5.5)1.4 (1.3 to NA)5.2 (3.6 to 9.3)3.4 (1.4 to 8.2)5.5 (2.7 to 11.0)4.3 (1.4 to 8.1)
SecondaryDuration of Bone Scan Response - NRE Cohorts, CRPC Only

The duration of BSR per IRF was calculated for CRPC subjects with an objective response (CR or PR) during the study.

Time frame:
From initial dose through final study visit up to 15 months
Reported as:
Median · months
Duration of Bone Scan Response - NRE Cohorts, CRPC Only
monthsNRE Cohort - CRPC 100 mgNRE Cohort - CRPC 39.4 mg
Duration of Bone Scan Response - NRE Cohorts, CRPC Only5.2 (4.07 to 6.67)NA (NA to NA)
SecondaryOverall Survival (OS) - NRE Cohorts, CRPC and Ovarian Only
Time frame:
From initial dose through final study visit up to 15 months
Reported as:
Median · months
Overall Survival (OS) - NRE Cohorts, CRPC and Ovarian Only
monthsNRE Cohort - CRPC 100 mgNRE Cohort - CRPC 39.4 mgNRE Cohort - Ovarian 100 mg
Overall Survival (OS) - NRE Cohorts, CRPC and Ovarian Only11.1 (9.17 to 13.34)8.0 (7.92 to NA)8.5 (5.88 to 11.73)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RDT All Cohorts54/526 (10.3%)223/526 (42.4%)524/526 (99.6%)
NRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer)53/93 (57%)53/93 (57%)93/93 (100%)
NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer)13/51 (25.5%)30/51 (58.8%)50/51 (98%)
NRE Cohort - Ovarian 100mg33/60 (55%)34/60 (56.7%)59/60 (98.3%)
Most frequent serious events
Showing 10 of 248
Most frequent serious events
EventRDT All CohortsNRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer)NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer)NRE Cohort - Ovarian 100mg
VomitingGastrointestinal disorders15/5267/930/5111/60
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders23/5267/938/511/60
NauseaGastrointestinal disorders12/5269/930/518/60
Abdominal PainGastrointestinal disorders9/5262/932/517/60
Small Intestinal ObstructionGastrointestinal disorders5/5260/930/515/60
Back PainMusculoskeletal and connective tissue disorders5/5265/934/510/60
Intestinal ObstructionGastrointestinal disorders3/5260/930/514/60
PyrexiaGeneral disorders5/5262/930/514/60
DehydrationMetabolism and nutrition disorders17/5266/932/510/60
Bone PainMusculoskeletal and connective tissue disorders0/5266/931/510/60
Most frequent other events
Showing 10 of 118
Most frequent other events
EventRDT All CohortsNRE Cohort - CRPC 100mg (Castration-Resistant Prostate Cancer)NRE Cohort - CRPC 39.4mg (Castration-Resistant Prostate Cancer)NRE Cohort - Ovarian 100mg
FatigueGeneral disorders345/52676/9332/5147/60
DiarrhoeaGastrointestinal disorders314/52666/9323/5146/60
Decreased AppetiteMetabolism and nutrition disorders270/52670/9322/5131/60
NauseaGastrointestinal disorders269/52664/9330/5136/60
Weight DecreasedInvestigations165/52642/9319/5118/60
VomitingGastrointestinal disorders188/52638/9319/5125/60
Abdominal PainGastrointestinal disorders120/52617/938/5123/60
DysgeusiaNervous system disorders156/52635/9314/5121/60
DysphoniaRespiratory, thoracic and mediastinal disorders142/52634/939/5116/60
ConstipationGastrointestinal disorders168/52632/9316/5121/60

Baseline characteristics

Age, Customized
Age, Customized(Participants)RDT Cohort - CRPCRDT Cohort - MelanomaRDT Cohort - NSCLCRDT Cohort - Pancreatic CancerRDT Cohort - GEJRDT Cohort - HCCRDT Cohort - SCLCRDT Cohort - Ovarian CancerRDT Cohort - MBCNRE Cohort - CRPC 100 mgNRE Cohort - CRPC 39.4 mgNRE Cohort - Ovarian Cancer 100mgTotal
<= 40 years05111404600123
> 40 - <= 50 years4631332127351059
> 50 - <= 65 years60282311922123226412433321
> 65 years107383378127226492216327
Sex: Female, Male
Sex: Female, Male(Participants)RDT Cohort - CRPCRDT Cohort - MelanomaRDT Cohort - NSCLCRDT Cohort - Pancreatic CancerRDT Cohort - GEJRDT Cohort - HCCRDT Cohort - SCLCRDT Cohort - Ovarian CancerRDT Cohort - MBCNRE Cohort - CRPC 100 mgNRE Cohort - CRPC 39.4 mgNRE Cohort - Ovarian Cancer 100mgTotal
Female0352775101270440060270
Male171423313163190193510460
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RDT Cohort - CRPCRDT Cohort - MelanomaRDT Cohort - NSCLCRDT Cohort - Pancreatic CancerRDT Cohort - GEJRDT Cohort - HCCRDT Cohort - SCLCRDT Cohort - Ovarian CancerRDT Cohort - MBCNRE Cohort - CRPC 100 mgNRE Cohort - CRPC 39.4 mgNRE Cohort - Ovarian Cancer 100mgTotal
American Indian or Alaska Native0000000000000
Asian1222011510111440
Native Hawaiian or Other Pacific Islander0000000001001
Black or African American112621310142235
White1457251181922186641854551633
More than one race3000000311019
Unknown or Not Reported01100111113212
08

Study locations

47 sites
  • Pinnacle Oncology of Arizona
    Scottsdale, Arizona 85258, United States
  • University of California Davis Cancer Center
    Sacramento, California 95817, United States
  • University of California, San Francisco
    San Francisco, California 94115, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33916, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • Medical College of Georgia
    Augusta, Georgia 30912, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Dana Farber Cancer Center
    Boston, Massachusetts 02115, United States
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • University of Missouri Health Care
    Columbia, Missouri 65203, United States
  • Kansas City Cancer Center
    Lee's Summit, Missouri 64064, United States
  • Midwest Hematology Oncology Consultants
    Saint Louis, Missouri 63136, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • NYU Clinical Cancer Center
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Ohio State University GYN Oncology
    Hilliard, Ohio 43026, United States
  • University of Oklahoma
    Oklahoma City, Oklahoma 73190, United States
  • Cancer Care Associates
    Tulsa, Oklahoma 74104, United States
  • Northwest Cancer Specialists
    Tualatin, Oregon 97062, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Cancer Centers of the Carolinas, ITOR
    Greenville, South Carolina 29605, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Texas Oncology - Central Austin Cancer Center
    Austin, Texas 78731, United States
  • Mary Crowley Medical Research Center
    Dallas, Texas 75246, United States
  • University of Texas, M. D., Anderson Cancer Center
    Houston, Texas 77030, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Fairfax Northern Virginia Hematology Oncology
    Fairfax, Virginia 22031, United States
  • University of Washington
    Seattle, Washington 98109, United States
  • One Study Location
    Brussels, Belgium
  • One Study Location
    Jette, Belgium
  • Multiple Study Locations
    Leuven, Belgium
  • Liege, Belgium
  • One Study Location
    Mons, Belgium
  • One Study Location
    Jerusalem, Israel
  • One Study Location
    Tel Aviv, Israel
  • One Study Location
    Tel-Hashomer, Israel
  • One Study Location
    Zerifin, Israel
  • Multiple Study Locations
    Tainan City, Taiwan
  • Chang Gung Medical Foundation, Taoyuan County
    Taipei, Taiwan
  • Taipei, Taiwan
  • One Study Location
    London, United Kingdom
09

References and documents

Publications

  • Schoffski P, Gordon M, Smith DC, Kurzrock R, Daud A, Vogelzang NJ, Lee Y, Scheffold C, Shapiro GI. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours. Eur J Cancer. 2017 Nov;86:296-304. doi: 10.1016/j.ejca.2017.09.011. Epub 2017 Oct 20. PubMed 29059635 ↗
  • Vergote IB, Smith DC, Berger R, Kurzrock R, Vogelzang NJ, Sella A, Wheler J, Lee Y, Foster PG, Weitzman R, Buckanovich RJ. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma. Eur J Cancer. 2017 Sep;83:229-236. doi: 10.1016/j.ejca.2017.06.018. Epub 2017 Jul 26. PubMed 28755607 ↗
  • Kelley RK, Verslype C, Cohn AL, Yang TS, Su WC, Burris H, Braiteh F, Vogelzang N, Spira A, Foster P, Lee Y, Van Cutsem E. Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. Ann Oncol. 2017 Mar 1;28(3):528-534. doi: 10.1093/annonc/mdw651. PubMed 28426123 ↗
  • Tolaney SM, Nechushtan H, Ron IG, Schoffski P, Awada A, Yasenchak CA, Laird AD, O'Keeffe B, Shapiro GI, Winer EP. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Res Treat. 2016 Nov;160(2):305-312. doi: 10.1007/s10549-016-4001-y. Epub 2016 Oct 6. PubMed 27714541 ↗
  • Leibowitz-Amit R, Pintilie M, Khoja L, Azad AA, Berger R, Laird AD, Aftab DT, Chi KN, Joshua AM. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial. J Transl Med. 2016 Jan 13;14:12. doi: 10.1186/s12967-015-0747-y. PubMed 26762579 ↗
  • Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol. 2014 Oct 20;32(30):3391-9. doi: 10.1200/JCO.2013.54.5954. Epub 2014 Sep 15. PubMed 25225437 ↗
  • Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort. Eur Urol. 2015 Feb;67(2):310-8. doi: 10.1016/j.eururo.2014.02.013. Epub 2014 Feb 20. PubMed 24631409 ↗
  • Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN Jr, Lin CC, Srinivas S, Sella A, Schoffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 1;31(4):412-9. doi: 10.1200/JCO.2012.45.0494. Epub 2012 Nov 19. PubMed 23169517 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2009 to primary completion in May 2013, 44 months.

Results were first posted in Apr 2024, 10 years 11 months after primary completion.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 44 months is close to that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 12, 2009
First posted
Jul 15, 2009
StartActual
Sep 2009
Primary completionActual
May 2013
CompletionActual
Jun 2014
Results first posted
Apr 25, 2024
Last update
Apr 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00940225
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Jul 15, 2009
Start date
Sep 2009
Primary completion
May 2013
Completion
Jun 2014
Results posted
Apr 25, 2024
Last update
Apr 25, 2024

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion